Quarterly Earnings

All articles by Quarterly Earnings

Earnings season week 3: BioNTech revenues, net profit drop
Earnings season week 3: BioNTech revenues, net profit drop
Jack O'Brien
August 8, 2022
10:46 am

Despite the financial dropoff, BioNTech reiterated its outlook for 2022.

More earnings: Amgen announces results and acquisition, Vertex product revenue hits $2.2B
More earnings: Amgen announces results and acquisition, Vertex product revenue hits $2.2B
Jack O'Brien
August 4, 2022
4:43 pm

Amgen will purchase ChemoCentryx, which focuses on orally administered treatments for autoimmune diseases, inflammatory disorders and cancer, for $3.7 billion.

Earnings season continues: Lilly revenue and net income slides
Earnings season continues: Lilly revenue and net income slides
Jack O'Brien
August 4, 2022
11:39 am

Revenue dropped 4% year-on-year, while net income fell 31%.

Pharma earnings roundup: Moderna and Gilead surge, Regeneron stumbles
Pharma earnings roundup: Moderna and Gilead surge, Regeneron stumbles
Jack O'Brien
August 3, 2022
9:54 am

Other healthcare organizations that released Q2 earnings reports included Seres Therapeutics, EyePoint Pharmaceuticals, United Therapeutics and G1 Therapeutics.

Pharma earnings roundup: AbbVie and AstraZeneca post top-line growth
Pharma earnings roundup: AbbVie and AstraZeneca post top-line growth
Jack O'Brien
July 29, 2022
9:48 am

AstraZeneca also announced that Michel Demaré would succeed Leif Johansson as Non-Executive Chair of the Board.

Earnings season continues: BMS revenue inches up, Teva lowers outlook
Earnings season continues: BMS revenue inches up, Teva lowers outlook
Jack O'Brien
July 27, 2022
10:28 am

Teva also provided an update on its $4.25 billion opioid settlement agreement.

Earnings week continues: Abbott’s infant formula sales and Biogen’s revenue slides
Earnings week continues: Abbott’s infant formula sales and Biogen’s revenue slides
Jack O'Brien
July 20, 2022
9:37 am

Despite the infant formula controversy, Abbott is raising its full-year EPS guidance.

Earnings week: Novartis expects reorg to save $1.5B, J&J sales grow by 3%
Earnings week: Novartis expects reorg to save $1.5B, J&J sales grow by 3%
Jack O'Brien
July 19, 2022
9:49 am

Novartis noted that its strategic review of Sandoz is “on track” and expected to be completed by the end of the year.

Group M and VMLY&R ease pain for WPP as Q3 drops 7.6%
Group M and VMLY&R ease pain for WPP as Q3 drops 7.6%
Gideon Spanier
October 29, 2020
9:43 am

VMLY&R in US and Group M in UK increased revenues.

Omnicom ends voluntary pay cuts as Q3 results improve
Omnicom ends voluntary pay cuts as Q3 results improve
Alison Weissbrot
October 27, 2020
9:05 am

Publicis and WPP have already phased out pay cuts.

  • From Our Partners